Preparation and evaluation of an experimental iscom-based infectious bursal disease vaccine

The present study was conducted to develop and evaluate an experimental ISCOM-based infectious bursal disease (IBD) vaccine. The indigenous very virulent infectious bursal disease virus (vvIBDV) already attenuated and adapted to Vero cell line was used. After denaturation of viral proteins with sodium dodecyl sulphate (SDS), an IBD-ISCOM was constructed. The non-incorporated viral components were separated from ISCOM by centrifugation of dialysate. The pathogenicity and immunogenicity trials were conducted in 3-week-old broiler chicken. A commercial oil-emulsified vaccine (CEVAC IBD K) was used for comparison. There were no clinical signs of disease, gross or microscopic lesions in bursa of Fabricius in group G1 vaccinated with ISCOM-based vaccine and bursa to body weight ratio were comparable to un-vaccinated control group (G3). The virus-neutralizing antibody titers were significantly (P<0.05) higher in group G1 as compared with group G2 which was vaccinated with commercial vaccine. On challenge with vvIBDV, 100%, 75% and 0.00% protection was achieved in G1, G2 and G3, respectively. The results indicated that ISCOM-based IBD vaccine is safe and immunogenic.     

鼠疫疫苗研究的现状与展望

鼠疫（Plague）是由鼠疫耶尔森菌(Yersina pestis，Y. pestis)（简称鼠疫菌）引起的一种烈性传染病，属甲类传染病，具有高度传染性和致病性。在过去的鼠疫大流行中近2亿感染者死亡。疫苗接种是疾病预防控制的重要方法。现就鼠疫疫苗的研究进展作一综述，为新疫苗的研制提供参考。     

微生物介导的恶性疟原虫PfMSP-1疫苗的研制现状

恶性疟原虫引起的恶性疟是一种严重危害人类健康的寄生虫病,采用疫苗防治该病是当前研究的热点领域之一。PfMSP-1抗原是一种有效的疫苗候选分子,鼠伤寒沙门菌、卡介苗、酵母菌、根癌农杆菌、嗜热四膜菌、腺病毒、牛痘病毒和杆状病毒等微生物经过改造后均可成为有希望的疫苗载体。本文综述了重组鼠伤寒沙门菌(rSt-PfMSP-1和rSt-PfMSP-1_(19))、重组BCG疫苗(rBCG-PfMSP-1c和rBCGPfMSP-1_(19))、重组酵母菌(rPp-PfMSP-1)、重组根癌农杆菌(rAt-PfMSP-1_(42)、rAt-PfMSP4/5和rAtPf38)、重组嗜热四膜菌(rTt-PfMSP-1_(19))、重组腺病毒(rAd5-PfMSP-1_(42)和rChAd63-PfMSP-1)、重组牛痘病毒(rVV-PfMSP-1和rVV-PfHGFSP)以及重组杆状病毒(rBDES-PfMSP-1_(19))的构建及其免疫机制的研制现状。     

Adjuvanted oral vaccines should not induce allergic responses to dietary antigens

Oral vaccines may contain adjuvants which might elicit allergies against dietary proteins. Four antigens were used to measure such an effect--ovalbumin, soya bean protein, lactalbumin and gluten. Neither guinea pigs nor mice showed IgE responses after oral administration of adjuvanted vaccines containing lactalbumin and gluten. No IgE responses were detected in mice with any of these antigens after oral immunization, but, in the guinea pig, nine out of 18 animals reacted to either ovalbumin or soya bean protein and none reacted to lactalbumin and gluten. It is concluded that the risk of allergy induction against normal dietary proteins is low but such tests should be applied to potential adjuvanted oral vaccines to measure any possible contraindication, especially with atopic individuals.     

The long-term economic effects of polio: Evidence from the introduction of the polio vaccine to Sweden in 1957

This study explores the impact an exogenous improvement in childhood health has on later-life outcomes. Using extensive and detailed register data from the Swedish Interdisciplinary Panel covering up to 2011, we follow individuals exposed to the introduction of the first vaccine against polio in Sweden (birth cohorts 1937–1966) until adulthood in order to quantify the causal effect of polio vaccination on long-term economic outcomes. The results show that, contrary to what has been found in the literature for other health-related interventions, including other vaccines, exposure to the vaccine against polio did not seem to have any long-term effects on the studied adult economic outcomes. Upon closer inspection of how the disease affects children, this might be explained by the fact that no scarring effects from exposure to high incidence of polio were found on adult income, educational achievement, or hospitalizations, which seems to suggest that those who contracted the illness but suffered only the milder symptoms of the disease made a full recovery and had no lifelong sequels as a consequence of the condition. The absence of scarring effects is hypothesized to be related to the pathology and epidemiology of the disease itself, which infects many, but scars only those who suffer the most recognizable paralytic symptoms.     

Watching Every Step of the Way: Junín Virus Attenuation Markers in the Vaccine Lineage

The Arenaviridae family includes several hemorrhagic fever viruses which are important emerging pathogens. Junín virus, a member of this family, is the etiological agent of Argentine Hemorrhagic Fever (AHF). A collaboration between the Governments of Argentina and the USA rendered the attenuated Junín virus vaccine strain Candid#1. Arenaviruses are enveloped viruses with genomes consisting of two single-stranded RNA species (L and S), each carrying two coding regions separated by a stably structured, non-coding intergenic region. Molecular characterization of the vaccine strain and of its more virulent ancestors, XJ13 (prototype) and XJ#44, allows a systematic approach for the discovery of key elements in virulence attenuation. We show comparisons of sequence information for the S RNA of the strains XJ13, XJ#44 and Candid#1 of Junín virus, along with other strains from the vaccine lineage and a set of Junín virus field strains collected at the AHF endemic area. Comparisons of nucleotide and amino acid sequences revealed different point mutations which might be linked to the attenuated phenotype. The majority of changes are consistent with a progressive attenuation of virulence between XJ13, XJ#44 and Candid#1. We propose that changes found in genomic regions with low natural variation frequencies are more likely to be associated with the virulence attenuation process. We partially sequenced field strains to analyze the genomic variability naturally occurring for Junín virus. This information, together with the sequence analysis of strains with intermediate virulence, will serve as a starting point to study the molecular bases for viral attenuation.     

Characterization of Brucella abortus S19 as a challenge strain for use in a mouse model of brucellosis

The objective of this project was to conduct a feasibility study to determine whether the Brucella abortus S19 vaccine infects and persists in mice and determine whether S19 can be used as a challenge strain for vaccine trial studies. Groups of BALB/c mice were inoculated (intraperitoneally, subcutaneously, intranasally) and euthanized to determine colonization titers in the spleens and lungs. This study showed that S19 does infect and persist in the tissues of mice for 8 weeks and demonstrates that S19 can be used, safely and economically under BSL2 containment, as the challenge strain for future trials to evaluate vaccine efficacy.     

GMP Production of Liposomes—A New Industrial Approach

A new scalable liposome production system is presented, which is based on the ethanol injection technique. The system permits liposome manufacture regardless of production scale, as scale is determined only by free disposable vessel volumes. Once the parameters are defined, an easy scale up can be performed by just changing the process vessels. These vessels are fully sterilizeable and all raw materials are transferred into the sanitized and sterilized system via 0.2 μm filters to guarantee an aseptic production.

Liposome size can be controlled by the local lipid concentration at the injection point depending on process parameters like injection pressure, lipid concentration and injection rate. These defined process parameters are furthermore responsible for highly reproducible results with respect to vesicle diameters and encapsulation rates Compared to other technologies like the film method which is normally followed by size reduction through high pressure homogenization, ultrasonication or extrusion, no mechanical forces are needed to generate homogeneous and narrow distributed liposomes.

Another important advantage of this method is the suitability for the entrapment of many different drug substances such as large hydrophilic proteins by passive encapsulation, small amphiphilic drugs by a one step remote loading technique or membrane association of antigens for vaccination approaches     

鼠伤寒沙门氏菌SL7207 SifA-突变株的构建和鉴定

鼠伤寒沙门氏菌SifA^-基因突变株的特点是能进入真核细胞的胞液。利用P22噬菌体转导技术构建了鼠伤寒沙门氏菌疫苗株SL7207的SifA^-突变株SL7207,该突变株与SL7207有着相似的体外生长曲线和细胞侵袭力,SL7207。在MDCK上皮细胞中的增殖能力增强,但在RAW264．7巨噬细胞中的生存能力减弱。小鼠毒力试验显示SL7207。在BALB／c小鼠体内毒力下降。仅SL7207在体外可向RAW264．7巨噬细胞递送真核表达质粒。SL7207的构建为重组沙门氏菌疫苗载体的研制提供了一个新的选择。